The anti-obesogenic metabolite, Lac-Phe, is elevated by metformin treatment in prostate cancer patients

ABSTRACT: Randomized clinical trials have highlighted the importance of weight control and exercise in improving cancer outcomes, yet the molecular mediators of these benefits remain poorly understood. Recent studies in Type 2 diabetic patients reported that the insulin-sensitizing drug, metformin, exerts its anorexigenic and anti-obesogenic effects through elevation of N-lactoyl-phenylalanine (Lac-Phe), a metabolite also reported to underlie the metabolic benefits of exercise in healthy individuals. Because metformin can be repurposed for oncology, we investigated whether the metformin/Lac-Phe link extends to cancer by profiling serum Lac-Phe levels in non-diabetic prostate cancer patients from BIMET-1, a prospective metformin trial, as well as those receiving metformin for metabolic dysfunction. I

SUBMITTER: Priyamvada Rai 

PROVIDER: S-SCDT-10_1038-S44321-026-00408-6 | biostudies-other |

REPOSITORIES: biostudies-other